| Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. | |
| | |
MedLine Citation:
|
PMID: 3154708 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Beta-adrenergic agonists can progressively lose their efficacy during chronic therapy in patients with heart failure. Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated. To assess whether any attenuation of its efficacy occurs, the variations of the cardiac output induced during chronic therapy were monitored by impedance cardiography in 15 patients with dilated cardiomyopathy who showed a significant increase of the cardiac output (20.7 +/- 10.0%) after acute ibopamine administration. The efficacy of ibopamine was also assessed after 6 and 12 months of therapy by echocardiography, exercise testing, and 24-hour dynamic electrocardiogram (EKG) monitoring. The cardiac output response to ibopamine did not show any significant attenuation (range 15% to 19%) in the evaluations at 1, 2, 3, 4, 8, and 12 months of therapy. No significant change, was noted, after 6 and 12 months, in the exercise capacity (505 vs. 602 and 604 seconds) and the fractional shortening (16.2 vs. 18.3 and 18.5) without any change of the diastolic diameter. Ventricular arrhythmias were significantly reduced after 6, but not 12, months of therapy. No significant change in the New York Association (NYHA) functional class was noted at 6 and 12 months of therapy (2.4 +/- 5 vs. 2.3 +/- 7 and 2.4 +/-0.6, respectively). Our results show that ibopamine can maintain its hemodynamic activity even during chronic therapy. |
| | |
Authors:
|
L Dei Cas; M Metra; S Nodari; S Riva; C Manca; O Visioli |
Related Documents
:
|
18671148 - Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive... 7647028 - Nicorandil safety in the long-term treatment of coronary heart disease. 22541318 - A novel method for the diagnosis of bacterial contamination in the anterior vagina of s... 18355868 - Hypertension is an indication for surgery in children with ureteropelvic junction obstr... 16935768 - Long-term primary medical therapy with somatostatin analogs in acromegaly. 22882208 - Facial skin barrier function recovery after microneedle transdermal delivery treatment. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy Volume: 2 ISSN: 0920-3206 ISO Abbreviation: Cardiovasc Drugs Ther Publication Date: 1988 Jul |
Date Detail:
|
Created Date: 1991-04-26 Completed Date: 1991-04-26 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8712220 Medline TA: Cardiovasc Drugs Ther Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 221-9 Citation Subset: IM |
Affiliation:
|
Cattedra di Cardiologia, Università degli Studi di Brescia, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Chronic Disease Deoxyepinephrine / analogs & derivatives*, therapeutic use Drug Tolerance Heart Failure / drug therapy*, physiopathology Humans Male Middle Aged Vasodilator Agents / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Vasodilator Agents; 501-15-5/Deoxyepinephrine; 66195-31-1/ibopamine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of nitrendipine and verapamil on plasma levels, urinary excretion, and beta-blocking effec...
Next Document: Effect of intravenous ketanserin on the human action potential duration at fixed heart rate.